DK2701697T3 - Oxidative nethindesygdomme - Google Patents
Oxidative nethindesygdomme Download PDFInfo
- Publication number
- DK2701697T3 DK2701697T3 DK12776521.2T DK12776521T DK2701697T3 DK 2701697 T3 DK2701697 T3 DK 2701697T3 DK 12776521 T DK12776521 T DK 12776521T DK 2701697 T3 DK2701697 T3 DK 2701697T3
- Authority
- DK
- Denmark
- Prior art keywords
- retinal diseases
- oxidative retinal
- oxidative
- diseases
- retinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479281P | 2011-04-26 | 2011-04-26 | |
| PCT/US2012/034836 WO2012148930A2 (en) | 2011-04-26 | 2012-04-24 | Oxidative retinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2701697T3 true DK2701697T3 (da) | 2020-06-29 |
Family
ID=47073024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12776521.2T DK2701697T3 (da) | 2011-04-26 | 2012-04-24 | Oxidative nethindesygdomme |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10058522B2 (da) |
| EP (2) | EP2701697B1 (da) |
| JP (2) | JP6106158B2 (da) |
| KR (2) | KR102110200B1 (da) |
| AU (1) | AU2012249921B2 (da) |
| CA (1) | CA2834341C (da) |
| DK (1) | DK2701697T3 (da) |
| IL (1) | IL229017B (da) |
| WO (1) | WO2012148930A2 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010313249B2 (en) | 2009-10-30 | 2016-05-19 | Biojiva Llc | Alleviating oxidative stress disorders with PUFA derivatives |
| JP6145087B2 (ja) | 2011-04-26 | 2017-06-07 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ酸化関与障害 |
| KR102020579B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | 에너지 프로세싱 손상 장애 및 미토콘드리아 결함 |
| KR102020611B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환 |
| KR102110200B1 (ko) | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | 산화성 망막 질환 |
| CA2941970A1 (en) * | 2014-03-13 | 2015-09-17 | Retrotope, Inc. | Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances |
| CN108698987B (zh) | 2015-11-23 | 2021-07-13 | 乐巢拓普有限公司 | 1,4-二烯体系的位点特异性同位素标记 |
| ITUB20169937A1 (it) | 2016-01-12 | 2017-07-12 | Medical And Biotechnological Services In Sigla M B S Srl | Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa |
| WO2018094116A1 (en) * | 2016-11-17 | 2018-05-24 | Retrotope, Inc. | Isotopically modified components and therapeutic uses thereof |
| US20220009950A1 (en) * | 2018-11-15 | 2022-01-13 | Retrotope, Inc. | Deuterated compounds, compositions, and methods of use |
| CA3141292A1 (en) * | 2019-05-28 | 2020-12-03 | Elgan Pharma Ltd | Compositions and methods for treating retinopathy |
| EP4103145A4 (en) * | 2020-02-12 | 2024-07-03 | Retrotope, Inc. | DEUTERATED POLYUNSATURATED FATTY ACIDS OR THEIR ESTERS FOR COSMETIC APPLICATIONS |
| CA3171330A1 (en) * | 2020-02-14 | 2021-08-19 | Retrotope, Inc. | Methods for treating tauopathy |
| KR20260018193A (ko) | 2020-02-21 | 2026-02-06 | 레트로토프 인코포레이티드 | 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정 |
| US11510889B2 (en) | 2021-02-05 | 2022-11-29 | Retrotope, Inc. | Methods for inhibiting the progression of neurodegenerative diseases |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| US11491130B2 (en) | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| EP4373479A4 (en) * | 2021-07-22 | 2025-11-05 | Biojiva Llc | METHODS FOR INHIBITING THE PROGRESSION OF OXIDATIVE RETINAL DISEASES |
| KR20240055796A (ko) * | 2021-09-03 | 2024-04-29 | 바이오지바 엘엘씨 | 중수소화 pufa를 이용한 세포 기능장애 및 세포 사멸의 억제를 위한 방법, 시스템 및 조성물 |
| US20240091187A1 (en) * | 2022-09-02 | 2024-03-21 | Biojiva Llc | Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof |
| KR102620997B1 (ko) * | 2022-11-10 | 2024-01-04 | 주식회사 아이두젠 | 노각나무 추출물을 유효성분으로 포함하는 시력 보호용 또는 망막 질환의 개선 및 예방용 조성물 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3520872A (en) | 1967-03-24 | 1970-07-21 | Upjohn Co | Process for labelling purine and pyrimidine containing compounds |
| US5340742A (en) | 1988-09-07 | 1994-08-23 | Omegatech Inc. | Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids |
| AU620929B2 (en) | 1988-10-27 | 1992-02-27 | Bar-Ilan University | Method and compositions for treating alzheimer's disease, related dementias and epilepsy |
| JPH07500566A (ja) | 1989-11-30 | 1995-01-19 | クロダ・インターナショナル・ピーエルシー | ネルボン酸及び長鎖脂肪酸の脱髄疾患の治療のための使用 |
| ES2033193B1 (es) | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | Mezcla grasa para nutricion infantil y de adultos. |
| US5436269A (en) | 1991-11-14 | 1995-07-25 | Sagami Chemical Research Center | Method for treating hepatitis |
| FR2721518B3 (fr) | 1994-06-28 | 1996-04-12 | Gattefosse Ets Sa | Compositions cosmétiques, pharmaceutiques, diététiques, vétérinaires contenant de l'eau. |
| GB9423625D0 (en) | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
| JPH08268885A (ja) | 1995-03-30 | 1996-10-15 | Oyo Seikagaku Kenkyusho | 過酸化脂質増量抑制剤 |
| US5578334A (en) | 1995-04-07 | 1996-11-26 | Brandeis University | Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends |
| CN1114878A (zh) | 1995-06-09 | 1996-01-17 | 郑州铁路局中心医院 | 一种防治心血管系统疾病的制剂 |
| JPH09143492A (ja) | 1995-11-17 | 1997-06-03 | Katsumasa Koike | 酸化脂質の確認方法及び酸化脂質の生成方法 |
| JPH10291955A (ja) | 1997-04-22 | 1998-11-04 | Sagami Chem Res Center | １３ｃ標識ドコサヘキサエン酸及びその製造方法 |
| US20030013772A1 (en) | 2000-02-23 | 2003-01-16 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
| US6111066A (en) | 1997-09-02 | 2000-08-29 | Martek Biosciences Corporation | Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains |
| AU750245B2 (en) | 1997-10-08 | 2002-07-11 | Aurinia Phamaceuticals Inc. | Deuterated cyclosporine analogs and their use as immunomodulating agents |
| US20030069208A1 (en) | 1997-11-25 | 2003-04-10 | University Of Otago | Mitochondrially targeted antioxidants |
| US6331532B1 (en) | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| US6270974B1 (en) | 1998-03-13 | 2001-08-07 | Promega Corporation | Exogenous nucleic acid detection |
| EP1075286A2 (en) | 1998-05-06 | 2001-02-14 | Isotechnika, Inc. | 13c glucose breath test for the diagnosis of diabetes |
| DK1121115T4 (da) * | 1998-10-15 | 2011-01-10 | Dsm Ip Assets Bv | PUFA-tilskud |
| IT1304406B1 (it) | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
| US20080275005A1 (en) | 1998-11-25 | 2008-11-06 | Murphy Michael P | Mitochondrially targeted antioxidants |
| US20070270381A1 (en) | 2000-05-25 | 2007-11-22 | Antipodean Pharmaceuticals, Inc. | Mitochondrially targeted antioxidants |
| US20060229278A1 (en) | 1998-11-25 | 2006-10-12 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| US6503478B2 (en) | 1999-01-13 | 2003-01-07 | Lightouch Medical, Inc. | Chemically specific imaging of tissue |
| US7271315B2 (en) | 1999-01-14 | 2007-09-18 | Martek Biosciences Corporation | PUFA polyketide synthase systems and uses thereof |
| JP2000290291A (ja) | 1999-03-31 | 2000-10-17 | Nippon Sanso Corp | 安定同位体標識オリゴヌクレオチド及びオリゴヌクレオチド検出方法 |
| ITMI991894A1 (it) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
| JP3432778B2 (ja) * | 1999-11-19 | 2003-08-04 | 森澤 紳勝 | 活性酸素消去剤の濃縮液、その製造方法および活性酸素消去剤パウダー |
| GB9929897D0 (en) | 1999-12-18 | 2000-02-09 | Slabas Antoni R | Improvements in or relating to conjugated fatty acids and related compounds |
| JP2001270832A (ja) | 2000-03-27 | 2001-10-02 | Ito En Ltd | 網膜障害予防剤 |
| GB2368339B (en) | 2000-10-26 | 2002-09-18 | Yissum Res Dev Co | Complex incorporating a plurality of antioxidants |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| NZ529339A (en) | 2001-05-30 | 2004-08-27 | Laxdale Ltd | Coenzyme Q and eicosapentaenoic acid (EPA) |
| GB0113348D0 (en) * | 2001-06-01 | 2001-07-25 | Mars Uk Ltd | Skin diet |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| IL160928A0 (en) | 2001-10-19 | 2004-08-31 | Maxim Pharm Inc | Use of histamine to treat liver disease |
| US6870077B2 (en) | 2002-01-30 | 2005-03-22 | Edward O. Kenaschuk | High linolenic acid flax |
| JP2004081156A (ja) | 2002-08-28 | 2004-03-18 | Shigeo Ota | 糖尿病および糖尿病関連疾患の予測のためのマーカーおよび個体分類方法 |
| WO2004029254A1 (ja) | 2002-09-30 | 2004-04-08 | Ajinomoto Co.,Inc. | 安定同位体標識タンパク質の製造方法 |
| WO2004028536A1 (en) | 2002-09-30 | 2004-04-08 | Babizhayev Mark A | Method for topical treatment of eye disease and composition and device for said treatment |
| BR0317026A (pt) | 2002-12-06 | 2005-10-25 | Alcon Inc | Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares |
| US7888334B2 (en) | 2003-08-22 | 2011-02-15 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| CN1839142B (zh) | 2003-08-22 | 2010-06-16 | 澳新制药公司 | 用作靶向线粒体的抗氧化剂的线粒体醌衍生物 |
| CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
| KR20050029582A (ko) | 2003-09-23 | 2005-03-28 | 주식회사 리포젠 | 알지닌 공액리놀레인산 복합체를 포함하는 항산화 조성물 |
| IL158552A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Lipids containing omega-3 fatty acids |
| EP1713463A4 (en) * | 2004-01-19 | 2009-03-18 | Martek Biosciences Corp | REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES |
| US20050164908A1 (en) | 2004-01-23 | 2005-07-28 | Ginsberg Myron D. | Neuroprotective complex for treatment of cerebral ischemia and injury |
| JP2008504372A (ja) | 2004-06-18 | 2008-02-14 | ニューロケム （インターナショナル） リミティッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| US20090232916A1 (en) | 2004-08-09 | 2009-09-17 | Avidor Shulman | Food products for diabetics |
| JP2006053100A (ja) | 2004-08-13 | 2006-02-23 | Institute Of Physical & Chemical Research | 動物の代謝解析方法、ラベル動物の製造方法、ラベル動物、および、動物のｎｍｒ測定方法 |
| JP2008520739A (ja) | 2004-11-19 | 2008-06-19 | マーテック・バイオサイエンシーズ・コーポレーション | 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法 |
| EP1834639B8 (en) | 2005-01-04 | 2016-12-07 | Mochida Pharmaceutical Co., Ltd. | Remedial agent for fat toxicity |
| US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| RU2444356C2 (ru) | 2005-07-08 | 2012-03-10 | Мартек Байосайенсиз Корпорейшн | Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией |
| ES2823728T3 (es) | 2005-09-15 | 2021-05-10 | Ptc Therapeutics Inc | Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía |
| FR2894577B1 (fr) * | 2005-12-14 | 2008-02-22 | Fabre Pierre Dermo Cosmetique | Nouveaux composes polyinsatures, leur procede de preparation et les compositions les contenant. |
| WO2007073560A2 (en) | 2005-12-20 | 2007-06-28 | Rnd Pharmaceuticals, Inc. | Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds |
| WO2007081773A2 (en) | 2006-01-05 | 2007-07-19 | Reliant Pharmaceuticals, Inc | Treatment of fatty liver |
| GB0604647D0 (en) | 2006-03-08 | 2006-04-19 | Shchepinov Mikhail | Stabilized food supplements and their derivatives |
| WO2008143642A2 (en) * | 2006-11-09 | 2008-11-27 | Children's Medical Center Corporation | Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids |
| US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| EP1961311A1 (en) | 2007-02-23 | 2008-08-27 | Belovo S.A., Egg Science & Technology | Food comprising polyunsaturated fatty acids for the prevention of chronic diseases |
| AU2008224869A1 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| US20080234197A1 (en) | 2007-03-19 | 2008-09-25 | Undurti N Das | Method(s) of stabilizing and potentiating the actions and administration of brain-derived neurotrophic factor (BDNF) |
| KR20100016140A (ko) | 2007-05-25 | 2010-02-12 | 산텐 세이야꾸 가부시키가이샤 | 가령 황반 변성의 예방 또는 치료제 |
| ES2700141T3 (es) | 2007-08-02 | 2019-02-14 | Gilead Biologics Inc | Anticuerpos inhibidores LOXL2 y usos de los mismos |
| US20090069354A1 (en) | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched gemcitabine |
| CA2708961C (en) | 2008-01-08 | 2017-03-28 | Ptc Therapeutics, Inc. | (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| EP2245166A4 (en) | 2008-01-28 | 2012-12-05 | Univ Oklahoma | VERY LOW-CHAIN MULTIPLE UNSATURATED FATTY ACIDS, MANUFACTURING METHODS AND USES |
| US8637486B2 (en) | 2008-03-14 | 2014-01-28 | Retrotope, Inc. | Therapeutic substances that modulate genome methylation |
| CA2715036A1 (en) | 2008-03-14 | 2009-09-17 | Retrotope, Inc. | Therapies for cancer using isotopically substituted lysine |
| WO2009145982A1 (en) | 2008-04-01 | 2009-12-03 | Antipodean Pharmaceuticals, Inc. | Compositions and methods for skin care |
| EP2110027A1 (en) * | 2008-04-01 | 2009-10-21 | Nestec S.A. | Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation |
| WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
| WO2009134383A2 (en) | 2008-05-01 | 2009-11-05 | Complexa Inc. | Vinyl substituted fatty acids |
| WO2009151125A1 (ja) | 2008-06-13 | 2009-12-17 | 持田製薬株式会社 | 肝障害の診断及び治療 |
| GB0813599D0 (en) | 2008-07-24 | 2008-09-03 | Pharma Marine As | Method |
| EP3586839A1 (en) | 2008-07-28 | 2020-01-01 | Blanchette Rockefeller Neurosciences, Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
| US20100029706A1 (en) | 2008-07-30 | 2010-02-04 | Edison Parmaceuticals, Inc. a Delaware Corporation | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS |
| AU2009324495B2 (en) | 2008-12-11 | 2015-12-24 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| US20120046363A1 (en) | 2009-05-11 | 2012-02-23 | University Of Maryland, Baltimore | Docosahexaenoic acid for the treatment of heart failure |
| WO2010143053A1 (en) | 2009-06-10 | 2010-12-16 | Energy4Life Ag | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders |
| CA2781276A1 (en) | 2009-10-02 | 2011-04-07 | Complexa, Inc. | Heteroatom containing substituted fatty acids |
| AU2010313249B2 (en) * | 2009-10-30 | 2016-05-19 | Biojiva Llc | Alleviating oxidative stress disorders with PUFA derivatives |
| WO2011097273A1 (en) | 2010-02-02 | 2011-08-11 | Martek Biosciences Corporation | Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine |
| EP2641891B1 (en) | 2010-11-16 | 2019-07-03 | Nishizaki Bioinformation Research Institute | PKC-epsilon ACTIVATOR |
| JP6145087B2 (ja) | 2011-04-26 | 2017-06-07 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ酸化関与障害 |
| KR102020579B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | 에너지 프로세싱 손상 장애 및 미토콘드리아 결함 |
| KR102020611B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환 |
| KR102110200B1 (ko) | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | 산화성 망막 질환 |
| WO2012174262A2 (en) | 2011-06-14 | 2012-12-20 | Cenestra Llc | Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations |
-
2012
- 2012-04-24 KR KR1020197024381A patent/KR102110200B1/ko active Active
- 2012-04-24 DK DK12776521.2T patent/DK2701697T3/da active
- 2012-04-24 CA CA2834341A patent/CA2834341C/en active Active
- 2012-04-24 AU AU2012249921A patent/AU2012249921B2/en active Active
- 2012-04-24 US US14/113,547 patent/US10058522B2/en active Active
- 2012-04-24 JP JP2014508489A patent/JP6106158B2/ja active Active
- 2012-04-24 KR KR1020137031224A patent/KR102014524B1/ko active Active
- 2012-04-24 EP EP12776521.2A patent/EP2701697B1/en active Active
- 2012-04-24 EP EP20164359.0A patent/EP3689342A1/en active Pending
- 2012-04-24 WO PCT/US2012/034836 patent/WO2012148930A2/en not_active Ceased
-
2013
- 2013-10-22 IL IL229017A patent/IL229017B/en active IP Right Grant
-
2017
- 2017-03-03 JP JP2017040096A patent/JP6374551B2/ja active Active
-
2018
- 2018-08-21 US US16/106,838 patent/US11285125B2/en active Active
-
2022
- 2022-03-28 US US17/705,708 patent/US20220304968A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6374551B2 (ja) | 2018-08-15 |
| JP6106158B2 (ja) | 2017-03-29 |
| CA2834341A1 (en) | 2012-11-01 |
| KR102014524B1 (ko) | 2019-08-26 |
| EP3689342A1 (en) | 2020-08-05 |
| US10058522B2 (en) | 2018-08-28 |
| US20220304968A1 (en) | 2022-09-29 |
| JP2014514328A (ja) | 2014-06-19 |
| IL229017A0 (en) | 2013-12-31 |
| AU2012249921B2 (en) | 2017-06-08 |
| US11285125B2 (en) | 2022-03-29 |
| EP2701697A2 (en) | 2014-03-05 |
| EP2701697A4 (en) | 2014-10-15 |
| IL229017B (en) | 2020-09-30 |
| US20190046491A1 (en) | 2019-02-14 |
| WO2012148930A3 (en) | 2013-01-31 |
| KR20140036199A (ko) | 2014-03-25 |
| US20140044693A1 (en) | 2014-02-13 |
| WO2012148930A2 (en) | 2012-11-01 |
| JP2017125046A (ja) | 2017-07-20 |
| WO2012148930A8 (en) | 2013-12-12 |
| KR102110200B1 (ko) | 2020-05-13 |
| KR20190100455A (ko) | 2019-08-28 |
| EP2701697B1 (en) | 2020-03-25 |
| CA2834341C (en) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| IL229017B (en) | Oxidative retinal diseases | |
| EP2782540A4 (en) | CHAIR WITH ROLLERS | |
| DK2539015T3 (da) | Nethindeprotese | |
| BR112013032887A2 (pt) | cateter | |
| CO6852065A2 (es) | Galleta saludable | |
| EP2706957A4 (en) | PROCEDURE FOR NETWORK SKIN PROTESTS | |
| EP2663304A4 (en) | COMBINATION THERAPY | |
| HUE038714T2 (hu) | Dispiropirrolidin származék | |
| EP2673286A4 (en) | THERAPEUTIC COMPOUNDS | |
| EP2768423A4 (en) | OPHTHALMIC STRUCTURE | |
| EP2827759A4 (en) | FUNDUS CAMERA | |
| DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
| EP2726095A4 (en) | COMBINATION THERAPY | |
| FI20115876A0 (fi) | Yhdistelmähoito | |
| PT2750709T (pt) | Tratamento da caquexia | |
| DK2783256T3 (da) | Terapeutiske briller | |
| IL229081A0 (en) | Isoxazolines as therapeutic agents | |
| CO6880064A2 (es) | Métodos terapéuticos | |
| BR112014009761A2 (pt) | composição oftálmica | |
| PL2762466T3 (pl) | Pochodna fenylu | |
| EP2794550A4 (en) | OPHTHALMIC FORMULATION | |
| FI20115640A0 (fi) | Yhdistelmähoito | |
| EP2796096A4 (en) | MEDICAL PORT | |
| FI20115271A7 (fi) | Pohjallinen |